Guidelines

Challenging the Salt Restriction Norm

It is common practice to restrict dietary salt to alleviate or prevent “volume overload” in patients with acute decompensated heart failure (ADHF). But a new study reveals that this standard may be unnecessary. 

This double-blind randomized controlled trial investigated whether taking salt pills may actually benefit patients with ADHF undergoing intensive diuresis. Turns out, the approach made no difference to weight loss on diuresis (a proxy for volume reduction) or serum creatine levels in ADHF patients receiving high-dose IV diuretic therapy. 

The Cleveland Clinic researchers instructed 65 patients hospitalized with ADHF to take either placebo or 6mg salt per day (approximately equivalent to six servings of fast-food french fries) during diuresis for up to 96 hours. The primary endpoint was change in creatinine and weight at 96 hours.

  • The authors found that change in weight (–4 vs. –4.6 kg) and creatine (0.04 vs. 0.15 mg/dL) was comparable between the salt-ingesters and the placebo group. 
  • The authors also noted a smaller decrease in serum sodium (–0.03 vs. –2.6) and a smaller mean increase in blood urea nitrogen (3.1 vs. 11 mEq/L) in salt-ingesters versus the placebo group.
  • The trial was not powered to detect differences in serious adverse events, but the researchers reported that they observed none.

The Takeaway

These results challenge the routine practice of restricting salt consumption in ADHF cases. Nothing catastrophic happened when patients ingested salt in bulk; weight and creatine levels were similar between the experimental and control groups. 

Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Cardiology Business June 19, 2025

Lilly Buys Verve, Bringing Gene Editing Mainstream June 19, 2025

Gene editing for heart disease just got a major boost as Eli Lilly acquired Verve Therapeutics and its one-dose cholesterol drugs for up to $1.3B, marking a new path for Verve’s therapies to go mainstream. Part of the acquisition likely stems from Verve’s recent impressive trial results for its PCSK9-blocking treatment, VERVE-102, which lowered LDL-C […]

Cardiac Imaging June 19, 2025

New AI-driven Tool Aids in Mitral Valve Assessment June 19, 2025

By: Jimmy Su, Ph.D. Principal Scientist, Cardiovascular Ultrasound, Philips A new tool, Automated 3D Color Flow Quantification (3D Auto CFQ), removes the reliance on assumptions when quantifying mitral regurgitation and replaces it with a reliable and robust, AI-driven method that delivers precise measurement of mitral valve regurgitant volume (RVol) regardless of orifice shape and size. Eliminating assumptions: Quantification […]

Cardiology Pharmaceuticals June 16, 2025

No Need to Discontinue Abelacimab Pre-Procedure June 16, 2025

A new analysis of AZALEA-TIMI 71 suggests Anthos Therapeutics’ abelacimab is capable of reducing major bleeding in patients with AFib undergoing invasive procedures. The sub-analysis examined a total of 920 procedures across 441 patients taking either abelacimab or rivaroxaban, with approximately 1-in-3 patients undergoing an invasive procedure over a median follow-up of 2.1 years. Researchers […]

You might also like..

Select All

You're signed up!

It's great to have you as a reader. Check your inbox for a welcome email.

-- The Cardiac Wire Team

You're all set!